Tone mix
Week by week 52 weeks
Share of BeOne Medicines Ltd. American Depositary Shares's 176 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Mar 16, 2026 · tone -100Analysts' Downgrades for March 16th (AMOD, BDRFF, BELFB, EQR, HAIN, IMCR, INCY, IXHL, OEC, ONC)-117
- Week of Apr 27, 2026 · tone +100Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160+112
- Week of Jul 20, 2026 · tone +100BeOne Medicines Expands U.S. Manufacturing With $1 Billion Investment+69
- Week of Sep 29, 2025 · tone 0Here's Why BeOne Medicines Ltd. (ONC) Declined in Q2-66
- Week of Oct 27, 2025 · tone 0BeOne Medicines Ltd.: BeOne Medicines to Present at Upcoming Investor Conferences-60
- Week of Aug 24, 2026 · tone +100BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA+56
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about BeOne Medicines Ltd. American Depositary Shares in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 4 | +68 |
| Last 30 sessions | 11 | +52 |
| Last 90 sessions | 55 | +48 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
2 headlines, average tone +87: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.saultstar.com · 4 outletsBeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal CancerPositive
- www.finanznachrichten.de · 1 outletBeOne Medicines Ltd.: BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026Positive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer | www.saultstar.com | 4 | Positive |
| BeOne Medicines Ltd.: BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.investors.com · 2 outletsBeOne Medicines Breaks Out With Visions Of 177% Growth. This Clue Bodes Well.Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| BeOne Medicines Breaks Out With Visions Of 177% Growth. This Clue Bodes Well. | www.investors.com | 2 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletContrasting PainReform (NASDAQ:PRFX) & BeOne Medicines (NASDAQ:ONC)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Contrasting PainReform (NASDAQ:PRFX) & BeOne Medicines (NASDAQ:ONC) | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 19, 2026
2 headlines, average tone +100: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.nugget.ca · 7 outletsBeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026Positive
- iberonews.com · 1 outletBeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 - IberonewsPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 | www.nugget.ca | 7 | Positive |
| BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 - Iberonews | iberonews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 16, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletInsider Selling: BeOne Medicines (NASDAQ:ONC) Insider Sells 31,027 Shares of StockNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Insider Selling: BeOne Medicines (NASDAQ:ONC) Insider Sells 31,027 Shares of Stock | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about BeOne Medicines Ltd. American Depositary Shares, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.